New Meco “Botulinum Toxin Taiwan Taiwan Clinical Clinical Phase 1 patient administration”
Breaking News: Clinical Trials for Next-Gen Botulinum Toxin in Taiwan Advance Rapidly [서울=뉴시스] In a groundbreaking development, New Meco, a subsidiary of Botulinum Toxin, has successfully completed the first phase of clinical trials for its latest botulinum toxin product, Neurux, in Taiwan. This news signifies a significant step forward in the potential of next-generation cosmetic … Read more